Earlier this week, Catalent Pharma Solutions and Valerius Biopharma AG jointly announced their collaboration on the manufacture of Valerius’ specialty biosimilar products. According to the press release, Catalent Biologics will provide cell line development and support cGMP manufacturing activities from Phase I through to commercial stages. The collaboration will additionally involve the use of Catalent’s proprietary GPEx® technology, which according to Catalent and Valerius, creates high-performance, highly stable production cell lines in a wide variety of mammalian host cells.
The collaboration marks the latest in a series of partnerships, mergers, and acquisitions, including the completion of the business combination between Amneal Pharmaceuticals, LLC and Impax Laboratories, Inc., and Mylan’s partnership with Fujifilm Kyowa Kirin Biologics to commercialize a biosimilar adalimumab product.
The post Deal Watch: Catalent Biologics and Valerius Biopharma to Collaborate on Manufacture of Specialty Biosimilar Products appeared first on Big Molecule Watch.